Long-acting somatostatin analogues survival differences in limited- and extensive-disease SCLC patients.

Abstract

7051 Background: Long acting somatostatin analogues combined with platinum analogues have demonstrated an antiproliferative effect on growth of human SCLC xenografs. Methods: 114 (52 with limited disease) previously untreated SCLC patients with positive somatostatin receptors were included in the study. All patients performed 111In-Octreotide scanning before CHT, every 3 months and up to 4 times. All patients were treated with paclitaxel 190mg/m2+ carboplatin AUC=5.5 for up to 8 cycles. 48 hours after each CHT 30/114 patients (Group A) also received 30mg lanreotide (somatuline) in order to block somatostatine receptors for 2 weeks. 40/114 patients (Group B) received 60mg lanreotide to block somatostatine receptors for 4 weeks. 44/114 patients (Group C, control) received only CHT. No differences were observed between the 3 Groups regarding LD and ED patient ratios, age and PS. Patients in Groups A and B after the completion of the CHT continued maintenance therapy with lanreotide. Both non and hematological toxicity had no statistical significant differences between the Groups and generally toxicity was well managed. Results: Group A (median: 375.days, 95%CI: 206.3-543.7) had a survival benefit (p<0.001) in comparison to Group B (median: 347 days, 95%CI: 319.1-374.9 days). In limited disease patients group A had a statistical significant benefit compared to control group and to group B. 537 95% CI 449.8-624.2, 300 95%CI 244.2-355.8, 347 95%CI 187.9-506 respectively (p=0.04 Tarone-Ware test). Conclusions: Long acting somatostatin analogues could be used as an additive therapy in combination to antineoplastic agents in patients positive for somatostatine receptors. 30 mg dose improve survival only in limited disease SCLC patients. No significant financial relationships to disclose.